Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00944970 | Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia | PHASE3 | COMPLETED | 578 | — | — | Oct 1, 2005 | Dec 1, 2006 | Jun 1, 2012 | - | — |
| NCT00944294 | Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia | PHASE3 | COMPLETED | 419 | — | — | Feb 1, 2004 | Apr 1, 2006 | Jun 1, 2012 | - | — |
| Arm | Type | Description |
|---|---|---|
| binodenoson then adenosine | OTHER | binodenoson (experimental); adenosine (active comparator) |
| adenosine then binodenoson | OTHER | adenosine (active comparator); binodenoson (experimental) |
| adenosine then adenosine | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| binodenoson | DRUG | 30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo |
| adenosine | DRUG | 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute) |
Inclusion Criteria: * Able to understand and sign an informed consent form. Exclusion Criteria: * Women who are of childbearing potential. * Very low likelihood of coronary artery disease (by American Heart Association and American College of Cardiology standards). * Documented history of acute m...